Benzimidazole derivatives as dual histamine H1 and histamine H4 receptor ligands
US12134608B2 · kind B2 · utility
0Cited by
3References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 10, 2022 |
| Grant date | Nov 5, 2024 |
| Priority date | — |
| Expiry date | Feb 10, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present application concerns novel benzimidazole enantiomeric derivatives, their process of preparation and their therapeutical uses as dual H1 and H4 receptor ligands.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.